Du är här

2014-05-05

MagForce AG : MagForce AG and MagForce USA, Inc. Announce FDA Pre-IDE Meeting

MagForce AG / MagForce AG and MagForce USA, Inc. Announce FDA Pre-IDE Meeting.
Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is
solely responsible for the content of this announcement.
Berlin, Germany and Nevada, USA, May 5, 2014
- MagForce AG (Frankfurt, Entry Standard, XETRA: MF6), a leading medical
device company in the field of nanomedicine focused on oncology, together
with its subsidiary MagForce USA, Inc. are pleased to report that an
in-person meeting was held with the U.S. Food and Drug Administration's (FDA)
Center for Devices and Radiological Health to discuss FDA's response to
MagForce's NanoTherm® Therapy Pre-Submission of late December, 2013.

"We received very constructive feedback on our submission and have a better
understanding of the issues and process for registration of NanoTherm®
therapy in the USA. MagForce USA, Inc. will lead with the treatment of
recurrent Glioblastoma in concert with MagForce AG's post marketing clinical
trial in Germany, which has already begun enrolling patients. We are
confident that MagForce AG's extensive pre-clinical and clinical studies will
provide the background for a timely submission of an Investigational Device
Exemption (IDE) for the application of NanoTherm® Therapy,"commented Ben J.
Lipps, CEO of MagForce AG and MagForce USA.

Assisting MagForce with its USA registration efforts are Drs. Larry Kessler,
Professor and Chair of the Department of Health Services School of Public
Health, University of Washington, and Donna-Bea Tillman, Ph.D., M.P.A.,
FRAPS, of Biologics Consulting Group, Alexandria, VA.

About MagForce AG

MagForce AG, listed in the entry standard (MF6), together with its subsidiary
MagForce USA, Inc. is a leading medical device company in the field of
nanomedicine in oncology. The Group's proprietary, NanoTherm® therapy,
enables the targeted treatment of solid tumors through the intratumoral
generation of heat via activation of superparamagnetic nanoparticles.
NanoTherm®, NanoPlan®, and NanoActivator(TM) are components of the therapy
and have received EU-wide regulatory approval as medical devices for the
treatment of brain tumors. MagForce, NanoTherm®, NanoPlan®, and
NanoActivator(TM) are trademarks of MagForce AG in selected countries. For
more information, please visitwww.magforce.com.

Disclaimer

This release may contain forward-looking statements and information which may
be identified by formulations using terms such as "expects", "aims",
"anticipates", "intends", "plans", "believes", "seeks", "estimates" or
"will". Such forward-looking statements are based on our current expectations
and certain assumptions, which may be subject to a variety of risks and
uncertainties. The results actually achieved by MagForce AG may substantially
differ from these forward-looking statements. MagForce AG assumes no
obligation to update these forward-looking statements or to correct them in
case of developments, which differ from those, anticipated.

Contact
:

Anne Hennecke
MC Services AG

T +49 211 529252-22
F +49 211 529252-29
M +49 151 12 555 759

Email:anne.hennecke@mc-services.eu

MagForce_Press Release_May 05, 2014
http://hugin.info/143761/R/1782465/610112.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MagForce AG via Globenewswire

HUG#1782465

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.